BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 895 filers reported holding BAXTER INTL INC in Q1 2016. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $146,000 | -62.6% | 1,905 | -63.9% | 0.03% | -64.9% |
| Q2 2018 | $390,000 | -15.0% | 5,280 | -25.6% | 0.07% | -15.9% |
| Q4 2017 | $459,000 | -8.6% | 7,100 | -11.2% | 0.09% | -15.4% |
| Q3 2017 | $502,000 | +1.4% | 7,998 | -2.2% | 0.10% | -2.8% |
| Q2 2017 | $495,000 | +106.2% | 8,179 | +76.6% | 0.11% | +84.5% |
| Q1 2017 | $240,000 | +10.1% | 4,632 | -5.9% | 0.06% | -7.9% |
| Q4 2016 | $218,000 | -28.5% | 4,921 | -23.3% | 0.06% | -38.2% |
| Q3 2016 | $305,000 | -12.6% | 6,417 | -16.9% | 0.10% | -23.3% |
| Q2 2016 | $349,000 | -6.2% | 7,719 | -14.7% | 0.13% | -18.4% |
| Q1 2016 | $372,000 | -2.4% | 9,050 | -9.4% | 0.16% | -11.4% |
| Q4 2015 | $381,000 | -27.6% | 9,991 | -37.6% | 0.18% | -38.3% |
| Q3 2015 | $526,000 | -69.9% | 16,015 | -36.0% | 0.30% | -69.5% |
| Q2 2015 | $1,750,000 | -3.6% | 25,027 | -5.6% | 0.98% | -9.2% |
| Q1 2015 | $1,816,000 | -9.2% | 26,509 | -2.8% | 1.08% | -13.8% |
| Q4 2014 | $1,999,000 | -8.7% | 27,269 | -10.6% | 1.25% | -14.7% |
| Q3 2014 | $2,189,000 | -1.9% | 30,505 | -1.2% | 1.46% | -4.9% |
| Q2 2014 | $2,232,000 | -11.9% | 30,866 | -10.3% | 1.54% | -14.2% |
| Q1 2014 | $2,533,000 | +10.0% | 34,425 | +4.0% | 1.80% | -1.7% |
| Q4 2013 | $2,303,000 | – | 33,114 | – | 1.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |